19 November 2017
News and Views
Links and Services
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis, finds a study in December's issue of Gut.
Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors